Firefly Neuroscience, Inc. filings document the public-company disclosures of an AI precision-neuroscience business focused on EEG/ERP brain analytics and related software platforms. Its Form 8-K reports cover material financing agreements, including securities purchase agreements for unit issuances and at-the-market common stock sales arrangements, along with corporate events affecting its capital structure.
Proxy and annual meeting filings describe Firefly Neuroscience governance matters, including director elections, auditor ratification, incentive plan amendments, common stock voting mechanics and stockholder vote results. The filing record also provides formal disclosure context for the company’s operating model, commercialization activities, equity plan administration and governance obligations as a Nasdaq-listed Delaware corporation.
Firefly Neuroscience, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders. The meeting will be held on August 5, 2026 with the record date fixed as June 8, 2026. There were 15,064,571 shares outstanding as of the Record Date. The Board recommends voting for Proposals 1–6, which include election of Class III director(s), ratification of CBIZ Canada, LLP as auditors, an advisory vote on executive compensation, amendments to the 2024 Long-Term Incentive Plan, approval of an amendment to the certificate of incorporation to decrease authorized shares, and a proposal to adjourn if necessary. Proxy materials and the 2025 Form 10-K are available online.
Firefly Neuroscience, Inc. has terminated a previously agreed financing deal. The company and an accredited investor mutually ended a securities purchase agreement dated May 6, 2026, under which Firefly had planned to sell up to 666,667 units at $1.50 per unit, for potential gross proceeds of up to $1,000,000. The termination was agreed in writing and became effective on June 25, 2026, under Section 5.3 of the agreement. This update is reported as the termination of a material definitive agreement.
Firefly Neuroscience, Inc. registers up to 20,499,999 shares of common stock for resale. This preliminary prospectus covers resale by the identified Selling Stockholders of Registrable Securities issued in the March 2026 private placement, including shares issued and issuable upon exercise of related warrants.
The filing states the company will not receive proceeds from sales by the Selling Stockholders, although it may receive cash if the March 2026 Warrants are exercised for cash; full cash exercise at the stated exercise prices would generate approximately $29,929,998. Shares outstanding were 15,605,821 as of June 16, 2026, and outstanding after giving effect to the issuance described is shown as 36,105,820 in the prospectus.
Firefly Neuroscience, Inc. reports a change in the role and status of former Chief Technology Officer Gil Issachar. On June 18, 2026, Deel Innovation Ltd., which provides consulting services to Firefly, entered into an employment agreement with Issachar under which he now serves as Head of AI and Neuroscience for the company.
The new agreement supersedes all prior employment terms between Firefly and Issachar. Effective June 18, 2026, the board determined that Issachar is no longer classified as a Section 16 officer or executive officer of Firefly Neuroscience. The employment agreement is filed as Exhibit 10.1.
Firefly Neuroscience, Inc. registers up to 22,500,000 shares of common stock for resale by identified selling stockholders under a shelf prospectus. The registration covers shares issuable upon exercise of multiple warrant series from March and May 2026 private placements. Firefly will not receive proceeds from Selling Stockholder resales; the company may receive proceeds only if Warrants are exercised for cash. Shares outstanding were 15,571,780 as of May 15, 2026; outstanding after giving effect to the registered issuance is stated as 38,071,780.
Firefly Neuroscience, Inc. reported significantly higher quarterly revenue but continued losses and liquidity pressure. For the three months ended March 31, 2026, revenue rose to $485 thousand from $43 thousand, mainly from the Evoke Neuroscience acquisition, while net loss narrowed to $2.0 million from $12.9 million. Operating expenses were $2.2 million, similar to the prior year, and cash used in operations was $1.95 million.
The company ended the quarter with $3.1 million in cash and an accumulated deficit of $113.6 million, and its auditors and management stated that these conditions raise substantial doubt about its ability to continue as a going concern. To bolster liquidity, Firefly raised $2.4 million in Q1 2026 and a further $8.0 million in April through unit private placements, and it put in place a $7.4 million at-the-market stock offering and a pending up to $1.0 million units offering, all of which depend on market access.
Firefly Neuroscience, Inc. entered into a securities purchase agreement with an accredited investor for a private placement of up to 666,667 units at $1.50 per unit, for aggregate gross proceeds of up to $1,000,000. Each unit includes one share of common stock plus two five-year warrants, one exercisable at $1.88 per share and the other at $2.50 per share.
The warrants carry beneficial ownership limits of 4.99% or 9.99% and are not exercisable until stockholders approve the warrant share issuance. The closing depends on both stockholder approval and effectiveness of a resale registration statement on Form S-1 (or similar) covering the shares and warrant shares.
Firefly Neuroscience, Inc. completed an additional private financing closing, issuing 5,333,333 Units to an accredited investor for a total purchase price of $8,000,000 at $1.50 per Unit under its existing Securities Purchase Agreement.
The company and all investors entered into an Amended and Restated Lock-Up Agreement, restricting transfers of specified securities for a 30-day period ending on May 16, 2026, after which the lock-up securities will be fully released. In connection with this closing, investors also agreed to extend the deadline for the company to file a related Registration Statement with the SEC to May 21, 2026, with targeted effectiveness within 45 or 90 days after filing, depending on SEC review.
Firefly Neuroscience, Inc. files its annual report describing an AI-driven brain health platform built around its FDA-510(k) cleared Evoke System and Firefly analytics database. The system is deployed at more than 85 U.S. clinical sites, using a subscription model that ties revenue to assessment volume.
The company highlights a proprietary database of over 191,000 standardized EEG/ERP records across 12+ neurological and psychiatric disorders, and 23 issued U.S. patents supporting its technology. However, recurring losses, an accumulated deficit and negative operating cash flows raise substantial doubt about its ability to continue as a going concern without new capital.
FIREFLY NEUROSCIENCE, INC. filed an amended Form 3 updating insider holdings for Interim CEO Gregory Lipschitz. The amendment reports that 403,707 shares of common stock are held indirectly through Bower Four Capital Corporation, where he is the sole stockholder, and clarifies that he disclaims beneficial ownership except for his pecuniary interest. The shares were mistakenly omitted from the original Form 3 due to an error by the company’s SEC financial printer, so this amendment reflects a correction rather than a new transaction.